Arthroscopy for Femoroacetabular Impingement in Tonnis Grade 2 Arthritic Hips Results in Similar Clinical and Radiographic Outcomes but Lower Survivorship Than Tonnis Grades 0 and 1: A Systematic Review and Meta-analysis.

Am J Sports MedMay 24, 2026 (epub)
Clinical ResearchOrthopedic Surgery

Laura Krivicich, Alexis Driscoll, Madison Hayes-Lattin et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the impact of Tonnis grade on outcomes after hip arthroscopy for femoroacetabular impingement syndrome in 3972 hips. It found that Tonnis grade 2 hips had similar clinical outcomes compared to grades 0 and 1, but significantly lower survivorship, with higher rates of conversion to total hip arthroplasty (OR = 5.27).

Key findings

  • Tonnis grade 2 hips showed similar modified Harris Hip Score compared to grades 0 and 1 (SMD = -0.22).
  • Rates of revision arthroscopy were similar across Tonnis grades 0, 1, and 2 (OR = 1.65).
  • Tonnis grade 2 hips had significantly higher rates of conversion to total hip arthroplasty (OR = 5.27).

Why it matters

Understanding the relationship between Tonnis grade and postoperative outcomes can guide clinicians in predicting the success of hip arthroscopy and the likelihood of future interventions, such as total hip arthroplasty.

Source

PubMed · PMID 42178719

Published in Am J Sports Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.